Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Edgewise Therapeutics Inc EWTX

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:EWTX)

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Business Wire 10 days ago

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Business Wire December 5, 2024

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Business Wire November 26, 2024

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Business Wire November 7, 2024

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Business Wire October 1, 2024

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Business Wire September 19, 2024

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Business Wire September 17, 2024

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Business Wire August 8, 2024

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Business Wire May 10, 2024

Opinion & Analysis (NDAQ:EWTX)

No current opinion is available.

Bullboard Posts (NDAQ:EWTX)

(EWTX) Trading Advice

JUST IN: $EWTX (EWTX) Trading Advice2024-09-19 05:14:00 ET Stock Traders Daily has produced this trading report using a proprietary...
whytestocks - September 19, 2024

(EWTX) Proactive Strategies

Breaking News: $EWTX (EWTX) Proactive Strategies2024-06-21 10:32:00 ET Stock Traders Daily has produced this trading report using a...
whytestocks - June 21, 2024